Should I buy or sell Daiichi Sankyo stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" DSNKY shares. View DSNKY analyst ratings or view top-rated stocks .

How have DSNKY shares performed in 2024?

Daiichi Sankyo's stock was trading at $27.35 at the beginning of the year. Since then, DSNKY stock has increased by 10.3% and is now trading at $30.18. View the best growth stocks for 2024 here .

Are investors shorting Daiichi Sankyo?

Daiichi Sankyo saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 37,900 shares, an increase of 176.6% from the March 15th total of 13,700 shares. Based on an average trading volume of 265,400 shares, the short-interest ratio is presently 0.1 days. View Daiichi Sankyo's Short Interest .

Is Daiichi Sankyo a good dividend stock?

Daiichi Sankyo (OTCMKTS:DSNKY) pays an annual dividend of $22.47 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.

How do I buy shares of Daiichi Sankyo?

Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:DSNKY

Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free DSNKY Stock Alerts

$30.18

+0.60 (+2.03%)

(As of 04/19/2024 ET)

Compare

Today's Range: $29.92
▼
$30.43
50-Day Range: $29.15
▼
$34.22
52-Week Range: $23.72
▼
$37.57

Volume: 1.64 million shs
Average Volume: 135,003 shs
Market Capitalization: N/A

P/E Ratio: 0.26
Dividend Yield: 74.45%
Price Target: N/A

Stock Analysis Analyst Forecasts Chart Headlines Short Interest

Get Daiichi Sankyo alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Daiichi Sankyo Stock (OTCMKTS:DSNKY)

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.

DSNKY Stock Price History

30 days | 90 days | 365 days | Advanced Chart

DSNKY Stock News Headlines

April 11, 2024 | americanbankingnews.com

Short Interest in Daiichi Sankyo Company, Limited (OTCMKTS:DSNKY) Expands By 176.6%

March 13, 2024 | msn.com

MHRA authorises Daiichi Sankyo quizartinib for AML for marketing

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

March 2, 2024 | msn.com

Pfizer, Gilead, Roche seen benefitting the most from antibody-drug conjugates

February 25, 2024 | wsj.com

Daiichi Sankyo Co. Ltd. ADR

February 19, 2024 | finance.yahoo.com

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer

February 16, 2024 | morningstar.com

Daiichi Sankyo Co Ltd 4568

February 16, 2024 | news.yahoo.com

Daiichi invests 1 billion eur near Munich to make precision cancer drugs

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 16, 2024 | finance.yahoo.com

Daiichi invests 1 bln eur near Munich to make precision cancer drugs

February 2, 2024 | finance.yahoo.com

Q4 2023 Merck & Co Inc Earnings Call

January 25, 2024 | msn.com

What's Going On With Pfizer Stock Today?

January 17, 2024 | markets.businessinsider.com

US Patent Office Invalidates Seagen Patent In Daiichi Sankyo Dispute - Quick Facts

January 17, 2024 | finance.yahoo.com

U.S. Patent Office Invalidates Seagen Patent in Dispute between Daiichi Sankyo and Seagen

January 3, 2024 | marketwatch.com

Esperion Therapeutics, Daiichi Sankyo Europe Reach $125M Payment Agreement Over Commercial Litigation

January 3, 2024 | msn.com

Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today

December 22, 2023 | markets.businessinsider.com

Merck, Daiichi Sankyo Say FDA Grants Priority Review In U.S. For Patritumab Deruxtecan

December 22, 2023 | finance.yahoo.com

Patritumab Deruxtecan Granted Priority Review in the U.S. for Certain Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

December 17, 2023 | msn.com

Daiichi Sankyo Co., - ADR (DSNKY) Price Target Increased by 8.80% to 38.57

December 12, 2023 | businesswire.com

Depixus Announces Strategic Collaboration With Daiichi Sankyo to Use MAGNA™ Technology to Accelerate RNA-targeted Drug Discovery

December 1, 2023 | baystreet.ca

300,000 New Cases: The Role of Biotech in Addressing Rising Breast Cancer Rates

December 1, 2023 | businesswire.com

Daiichi Sankyo Demonstrates Breadth and Depth of Oncology Portfolio Across Multiple Cancers with New Data at ESMO Asia, SABCS and ASH

November 27, 2023 | finance.yahoo.com

Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo

October 31, 2023 | investing.com

Daiichi Sankyo Co., Ltd. (4568)

October 31, 2023 | finance.yahoo.com

Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?

October 26, 2023 | finance.yahoo.com

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

October 26, 2023 | finance.yahoo.com

‘Guided Missile Drugs’ Could Be Big Pharma’s Secret Weapon

See More Headlines

Receive DSNKY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Daiichi Sankyo and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Drug Manufacturers - General
Sub-Industry: N/A
Current Symbol: OTCMKTS:DSNKY
CUSIP: N/A
CIK: N/A
Web: www.daiichisankyo.com
Phone: (136) 225-1111
Fax: N/A
Employees: 17,435
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: 0.26
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Sunao Manabe D.V.M. (Age 70)
Ph.D., Group CEO & Executive Chairperson
Comp: $1.82M
Mr. Hiroyuki Okuzawa (Age 62)
President, COO & Representative Director
Comp: $713.24k
Mr. Masahiko Ohtsuki (Age 65)
Senior Managing Exec. Officer, Head of Global DX, Chief Digital Transformation Officer & Director
Comp: $713.24k
Dr. Shoji Hirashima (Age 63)
Senior Managing Executive Officer, Head of Japan Business Unit & Representative Director
Comp: $771.6k
Mr. Koji Ogawa
Managing Executive Officer, Head of Global Corporate Planning & Management and CFO
Chiyu
General Manager of Finance & Accounting Department
Hiroto Kashiwase
Managing Executive Officer, Head of Technology Management HQ and Head of Supply Chain HQ
Naoto Tsukaguchi
Gen. Counsel, Corp. Officer, Head of Global Leg., IP, Global Compl. and Risk & VP of Leg. Aff. Dept.
Kentaro Asakura
Vice President of Corporate Communications Department
Ms. Marielle Cohard-Radice M.D.
Global Head of Development

Key Competitors

View All Competitors

DSNKY Stock Analysis - Frequently Asked Questions

Should I buy or sell Daiichi Sankyo stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Daiichi Sankyo in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" DSNKY shares.
View DSNKY analyst ratings or view top-rated stocks.
How have DSNKY shares performed in 2024?: Daiichi Sankyo's stock was trading at $27.35 at the beginning of the year. Since then, DSNKY stock has increased by 10.3% and is now trading at $30.18.
View the best growth stocks for 2024 here.
Are investors shorting Daiichi Sankyo?: Daiichi Sankyo saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 37,900 shares, an increase of 176.6% from the March 15th total of 13,700 shares. Based on an average trading volume of 265,400 shares, the short-interest ratio is presently 0.1 days.
View Daiichi Sankyo's Short Interest.

Is Daiichi Sankyo a good dividend stock?: Daiichi Sankyo (OTCMKTS:DSNKY) pays an annual dividend of $22.47 per share and currently has a dividend yield of 3.12%. The dividend payout ratio is 19.59%. This payout ratio is at a healthy, sustainable level, below 75%.
How do I buy shares of Daiichi Sankyo?: Shares of DSNKY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:DSNKY) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Daiichi Sankyo (DSNKY) Stock Price, News & Analysis

About Daiichi Sankyo Stock (OTCMKTS:DSNKY)

DSNKY Stock Price History

DSNKY Stock News Headlines

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

DSNKY Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info